Exelixis Inc EXEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/16/21 EDT
23.59UNCH (UNCH)
Volume
77,249
Close
23.59quote price arrow down-0.36 (-1.50%)
Volume
1,639,476
52 week range
18.08 - 27.80

...

Loading . . .
  • Open23.91
  • Day High24.11
  • Day Low23.39
  • Prev Close23.95
  • 52 Week High27.80
  • 52 Week High Date05/12/20
  • 52 Week Low18.08
  • 52 Week Low Date04/15/20

Key Stats

  • Market Cap7.36B
  • Shares Out311.99M
  • 10 Day Average Volume1.55M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change17.54

KEY STATS

  • Open23.91
  • Day High24.11
  • Day Low23.39
  • Prev Close23.95
  • 52 Week High27.80
  • 52 Week High Date05/12/20
  • 52 Week Low18.08
  • 52 Week Low Date04/15/20
  • Market Cap7.36B
  • Shares Out311.99M
  • 10 Day Average Volume1.55M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change17.54

RATIOS/PROFITABILITY

  • EPS (TTM)0.35
  • P/E (TTM)67.57
  • Fwd P/E (NTM)70.42
  • EBITDA (MRQ)119.201M
  • ROE (MRQ)6.27%
  • Revenue (MRQ)987.54M
  • Gross Margin (MRQ)96.33%
  • Net Margin (MRQ)11.32%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Exelixis Inc

There is no recent news for this security.

Profile

MORE
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid...
Stelios Papadopoulos Ph.D.
Chairman
Michael Morrissey Ph.D.
Chief Executive Officer
Christopher Senner CPA
Chief Financial Officer
Patrick Haley
Executive Vice President
Jeffrey Hessekiel J.D.
Executive Vice President
Address
1851 Harbor Bay Pkwy
Alameda, CA
94502-3016
United States

Top Peers

SYMBOLLASTCHG%CHG
MEDP
Medpace Holdings Inc
179.90-5.10-2.76%
NBIX
Neurocrine Biosciences Inc
96.58+1.58+1.66%
SAGE
SAGE Therapeutics Inc
74.64-0.86-1.14%
SRPT
Sarepta Therapeutics Inc
71.80-0.83-1.14%
NVTA
Invitae Corp
37.64-1.42-3.64%